
==== Front
Epidemiol Health
Epidemiol Health
EPIH
Epidemiology and Health
2092-7193
Korean Society of Epidemiology

38697862
10.4178/epih.e2024046
epih-46-e2024046
Original Article
Causal effect of serum matrix metalloproteinase levels on venous thromboembolism: a Mendelian randomization study
http://orcid.org/0000-0003-1752-2203
Han Deheng
http://orcid.org/0009-0002-0207-6941
Yu Fangcong
http://orcid.org/0000-0002-3998-1999
Zheng Liangrong
Department of Cardiology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
Correspondence: Liangrong Zheng Department of Cardiology, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou 310003, China E-mail: 1191066@zju.edu.cn
2024
7 4 2024
46 e20240466 3 2024
26 3 2024
© 2024, Korean Society of Epidemiology
2024
https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
OBJECTIVES

Serum matrix metalloproteinase (MMP) levels are associated with cardiovascular diseases. However, the causal associations between serum levels of specific MMPs and venous thromboembolism (VTE) remain unclear. The present study sought to explore the causal relationship between serum MMP levels and VTE by using the Mendelian randomization (MR) method.

METHODS

In this study 2-sample MR study, the exposure data on serum MMP levels were derived from genome-wide association studies involving 21,758 individuals from 13 cohorts of European descent. The outcome data on VTE, including deep vein thrombosis and pulmonary embolism, were derived from the FinnGen research project. The primary method used was the inverse-variance weighting method. The MR-Egger intercept test and the Cochran Q test were used to evaluate pleiotropy and heterogeneity.

RESULTS

Using the inverse-variance weighting method, higher serum MMP-12 levels were found to be associated with an increased risk of VTE (odds ratio, 1.04; 95% confidence interval, 1.01 to 1.07; p=0.001). Moreover, there was a weak association between the levels of certain MMPs and VTE. Sensitivity analyses revealed no significant heterogeneity and pleiotropy in our study, and the Steiger directionality test did not reveal a significant reverse causation association.

CONCLUSIONS

There is a causal association between MMP-12 levels and VTE, which may have substantial implications for the diagnostic and therapeutic strategies used for VTE.

Venous thromboembolism
Mendelian randomization analysis
Matrix metalloproteinases
Pulmonary embolism
Venous thrombosis
==== Body
pmcGRAPHICAL ABSTRACT

Key Message

We found that there is a causal association between matrix metalloproteinase-12 levels and venous thromboembolism. Serum matrix metalloproteinase may have profound implications on the diagnostic andtherapeutic strategies used for venous thromboembolism.

INTRODUCTION

Venous thromboembolism (VTE) is a multicausal disease that includes pulmonary embolism (PE) and deep vein thrombosis (DVT). It ranks as the third most common cardiovascular disease, affecting nearly 10 million people worldwide annually [1-3]. VTE is associated with both inherited genetic factors and acquired conditions, such as cancer, obesity, surgery, and infection [1,4]. Understanding the pathophysiological mechanisms and risk factors associated with VTE is crucial for its effective prevention, diagnosis, and treatment.

Matrix metalloproteinases (MMPs) belong to the zinc-dependent endopeptidase family and have the ability to degrade virtually all constituents of the extracellular matrix, including elastin, fibronectin, and collagen, thereby promoting tissue repair and regeneration [5,6]. MMPs help maintain the delicate balance between extracellular matrix turnover and homeostasis under physiological conditions. Recent studies have revealed that MMPs can also participate in immune regulation, transcriptional control, and cell signaling [7]. Understanding the intricate biology of MMPs and their regulatory mechanisms has spurred advancements in basic, preclinical, and clinical investigations. Clinical trials have particularly focused on the effectiveness of MMP inhibitors in treating a variety of diseases, including cardiovascular, neurological, oncological, and inflammatory conditions [8-11].

Mendelian randomization (MR) is a statistical method used to evaluate causal relationships by leveraging genetic variants as instrumental variables (IVs) [12]. Using genetic variants as IVs can prevent reverse causation and confounding bias, enabling a more accurate assessment of the causal relationship between exposures and outcomes [13-15].

To our knowledge, relatively few studies have investigated the relationship between MMP levels and VTE. The current study aimed to examine the causal effect of MMP levels on VTE (including PE and DVT). By elucidating the role of MMPs in VTE, we hope to identify novel diagnostic and therapeutic targets that can ultimately improve patient outcomes and reduce the burden of this life-threatening condition.

MATERIALS AND METHODS

Study design

This study utilized a 2-sample MR design to explore the causal associations between serum MMP levels and the occurrence of VTE (including PE and DVT). An MR study is based on 3 core assumptions. First, the instrumental variable is strongly associated with the exposure. Second, the instrumental variable is independent of confounders. Third, the instrumental variable affects the outcome solely via the exposure (Figure 1) [13-15].

Data source

The genetic variants associated with serum MMP levels were identified in a study by Folkersen et al. [16]. This research evaluated 90 candidate biomarkers linked to cardiovascular risk in 21,758 individuals across 1,313 cohorts of European descent. The statistical data are available for download from the SCALLOP CVD-I online resource.

The FinnGen Project is a substantial public-private initiative that aims to collect and analyze genome and health data from 500,000 participants in Finnish biobanks. We extracted summary-level GWAS data for VTE (including DVT and PE) from the FinnGen consortium (Release 9, https://r9.finngen.fi/). This dataset included 19,372 cases and 357,905 controls for VTE (Phenocode: I9_VTE), 9,109 cases and 324,121 controls for DVT (Phenocode: I9_PHLETHROMBDVTLOW), and 9,243 cases and 367,108 controls for PE (Phenocode: I9_PULMEMB). The definitions of VTE, DVT, and PE were based on the International Classification of Diseases, ninth revision.

Selection of instrumental variables

We selected the single nucleotide polymorphisms (SNPs) to be used as IVs based on the following criteria: First, SNPs were strongly associated with the MMP (p < 5 × 10−8). Second, to prevent weak instrument bias, the F-statistic for each SNP was greater than 10. Third, linkage disequilibrium clumping was used to exclude SNPs in linkage disequilibrium (R2 < 0.1 and distance < 10,000 kb) [17,18]. Fourth, the MR pleiotropy residual sum and outlier (MR-PRESSO) test was used to remove potentially pleiotropic SNPs [19]. Fifth, to prevent reverse causality, Steiger filtering was used to identify SNPs indicative of causality in the reverse direction, which were then removed [20,21]. The detailed SNP statistics are presented in the Supplementary Material 1. These include the SNP, sample size, effect allele, other allele, β, standard error, p-value, effect allele frequency (EAF), and the number of SNPs for the exposures and outcomes of all analyses.

Statistical analysis

The primary method used for this analysis was the random-effect inverse-variance weighting (IVW) method [20]. Complementary methods included the weighted mode, weighted median, MR-Egger, and simple mode methods. The MR-Egger intercept test and the Cochran Q test were utilized to assess horizontal pleiotropy and heterogeneity, respectively [22]. A p-value < 0.05 indicated the presence of horizontal pleiotropy and heterogeneity. We employed the MR-PRESSO method to identify heterogeneous outlier SNPs and to provide a corrected estimate after their removal [23,24].

To prevent reverse causality, Steiger filtering was employed to identify SNPs indicative of causality in the opposite direction. Additionally, the MR-Steiger directionality test was utilized in our analysis [21]. To mitigate the risk of weak instrument bias, the Fstatistic for each SNP was calculated. R2 represents the variance explained by each SNP, calculated as R2 = 2× (1−EAF)×β2 × EAF; F=R2/(1−R2)× (N−2). Here, β represents the effect size; EAF denotes the EAF; and N is the number of individuals [25,26]. Power calculations were conducted using the online tool mRnd, based on the outcome sample size, proportion of cases, R2 sum, and a type I error rate of 0.05 [27,28].

A scatter plot and leave-one-out plot were utilized to visualize the results of our study. Given the multiple analyses conducted, a Bonferroni-corrected p-value of less than 0.0033 (0.05/15) was deemed statistically significant. A p-value between 0.003 and 0.050 was considered suggestive evidence. The analyses were performed using R version 4.2.3 (R Foundation for Statistical Computing, Vienna, Austria) and the TwoSampleMR R package.

Ethics statement

No patients were directly involved in the overall process of our study. This study was performed based on publicly available data and no separate ethical approval was required.

RESULTS

Primary Mendelian randomization analysis

Figure 2 presents the primary results of this MR study using the IVW method. A p-value less than 0.003 was considered statistically significant, while a p-value ranging from 0.003 to 0.050 was regarded as suggestive evidence. Seven trait pairs exhibited statistically significant differences before the Bonferroni correction was applied. Serum MMP-1 levels were associated with an increased risk of PE (odds ratio [OR], 1.06; 95% confidence interval [CI], 1.01 to 1.10; p= 0.010). Serum MMP-3 levels were associated with a higher risk of DVT (OR, 1.05; 95% CI, 1.01 to 1.09; p= 0.012) and a lower risk of PE (OR, 0.95; 95% CI, 0.92 to 0.99; p= 0.006). Serum MMP-7 levels were associated with a lower risk of PE (OR, 0.90; 95% CI, 0.84 to 0.97; p= 0.005). Serum MMP-10 levels were associated with a higher risk of VTE (OR, 1.04; 95% CI, 1.00 to 1.08; p = 0.046). Serum MMP-12 levels were associated with a higher risk of VTE (OR, 1.04; 95% CI, 1.01 to 1.07; p= 0.001) and PE (OR, 1.06; 95% CI, 1.02 to 1.10; p= 0.005). However, after applying the Bonferroni correction, only the association between serum MMP-12 levels and a higher risk of VTE remained significant. The scatter plots of significant MR results before the Bonferroni correction are displayed in Figure 3.

Sensitivity tests

The weighted mode, MR-Egger, and weighted median methods were used to evaluate the causal association between MMP levels and VTE (including DVT and PE). Although several associations did not show statistical significance, the results were in the same direction as those obtained using the primary IVW method (Supplementary Material 2).

The pleiotropy of the study was evaluated using the MR-Egger regression method, and no significant pleiotropy was detected in our analyses (p for intercept > 0.05). The study’s heterogeneity was assessed with the Cochran Q test, and no significant heterogeneity was observed in our analyses, except for the association between MMP-12 levels and PE (Table 1). Due to the presence of heterogeneity, both the MR-PRESSO outlier test and leave-one-out analysis were conducted to identify and eliminate outlier SNPs (Supplementary Material 3). Additionally, random-effect models were employed in our analysis to reduce the impact of heterogeneity. The MR-Steiger directionality test yielded a result of “true” for all tests, indicating the absence of reverse causal associations.

The statistical power for the main analyses met the 80% threshold, with the exception of the association between MMP-10 and VTE (Supplementary Material 4). This discrepancy may be attributed to the minimal variance in MMP-10 explained by the selected IVs. Therefore, caution is advised when interpreting this particular result. Overall, however, our results are considered relatively reliable.

DISCUSSION

In our study, we employed the MR method to explore the causal relationship between serum MMP levels and the incidence of VTE, which includes DVT and PE. Following Bonferroni correction, the findings suggested that elevated serum MMP-12 levels are associated with an increased risk of VTE.

To our knowledge, this study is the first to explore the causal relationship between serum MMP levels and VTE. VTE is a disease with multiple causes, including inherited genetic factors and acquired factors. It is also a common complication in patients who are bedridden for extended periods and those who have undergone surgery [1,4]. In clinical practice, D-dimer serves as a crucial laboratory marker for patients at low risk, boasting a sensitivity of up to 95% in diagnosing VTE. However, its specificity is low [29]. Therefore, it is necessary to identify new biomarkers that offer both high sensitivity and specificity.

Some clinical and basic foundational studies have investigated the association between MMPs and thrombi. One study found that the upregulation of MMPs is involved in left atrial appendage thrombus formation in elderly people [30]. Another study demonstrated a disequilibrium of MMPs in the superficial venous wall in patients with superficial venous thrombosis. Therefore, MMPs may be implicated in the pathogenesis of superficial venous thrombosis [31]. Furthermore, in a mouse model of myocardial infarction, increased MMP levels were associated with the formation of intracardiac thrombi [32].

Previous studies also investigated the causal effect of MMP levels on ischemic stroke through MR. The first study examined the causal effects of MMP-1, MMP-8, and MMP-12 levels on ischemic stroke. It found that lower serum levels of MMP-12 were associated with an increased risk of ischemic stroke, lower serum levels of MMP-1 and MMP-12 were linked to an increased risk of large-artery stroke, and higher serum levels of MMP-8 were associated with an increased risk of small vessel stroke [33]. The second Mendelian study focused on the association between MMP-8 levels and ischemic stroke and its subtypes, finding that higher serum levels of MMP-8 were associated with increased risks of small vessel stroke [34]. The third Mendelian study investigated promising therapeutic targets for ischemic stroke identified from plasma and cerebrospinal fluid proteomes. Using different databases, it found that lower serum levels of MMP-12 were associated with an increased risk of ischemic stroke [35]. These 3 MR studies showed relatively consistent results.

However, epidemiological studies investigating the association between MMP-8 levels and the risk of stroke have yielded inconsistent results; several studies have demonstrated a significant correlation [36,37], while others have not [38,39]. There are many reasons for this divergence. First, observational studies suffer from several methodological limitations for causal inference, including inherent biases such as confounding and reverse causation. Second, the databases for stroke in MR studies were mainly from individuals of European descent, whereas the observational cohort was ethnically diverse. Third, the clotting process during serum preparation is known to release MMPs from circulating leukocytes. Therefore, measuring this proteinase from serum also reflects the potential of the neutrophils to degranulate and release it, and this degree may depend on genetic variations [40]. Overall, larger studies are needed to confirm the causal relationships between serum MMP levels and stroke.

Although the precise relationship between MMP-12 levels and VTE is not fully understood, with ongoing research, blood stasis, endothelial damage, and hypercoagulability are recognized as the three primary components of thrombosis [41]. MMP-12 was first identified and characterized in macrophages [42,43]. This macrophage-derived MMP-12 can break down the protein that connects endothelial cells, resulting in cell apoptosis and injury [43]. Additionally, in a model of vascular injury, biomarkers associated with vascular damage were found to be reduced in MMP-12 knockout mice [44].

In addition to its degradative mechanism, MMP-12 promotes inflammatory responses, which are crucial for the development of thrombosis. In mice with MMP-12 overexpression, there is an increase in chemokine secretion and the recruitment of inflammatory cells, such as macrophages, to the sites of inflammation [45]. In MMP-12 knockout mice, the inflammation was comparatively more attenuated than in control mice [46].

Furthermore, MMP-12 has been implicated in the regulation of fibrinolysis, a process in which blood clots are broken down [47]. It inhibits fibrinolysis by degrading plasminogen activators, which are essential for the breakdown of fibrin clots. This inhibition may contribute to the persistence and growth of blood clots in VTE [48,49]. Overall, the relationship between MMP-12 levels and VTE involves vascular injury, modulation of inflammatory responses, and regulation of fibrinolysis. However, further research is needed to fully understand the complex interactions and potential mechanisms involved in this association.

In our analysis, before applying the Bonferroni correction, serum MMP-3 levels were associated with an increased risk of DVT (OR, 1.05; 95% CI, 1.01 to 1.09; p= 0.012) and a decreased risk of PE (OR, 0.95; 95% CI, 0.92 to 0.99; p= 0.006). However, these associations disappeared after the Bonferroni correction was applied. PE comprises a group of clinical syndromes characterized by the obstruction of the pulmonary artery or its branches by various emboli. These emboli can include materials such as thrombus, fat, air, amniotic fluid, bone marrow, metastatic cancer, bacteria, and cardiac organisms. DVT involves the clotting of venous blood within the deep veins of the lower extremities and does not necessarily result in PE. Further research is required to elucidate these discrepancies.

All results presented in this study were based on the IVW method. Various types of sensitivity analysis further confirmed the strength and reliability of our findings. The IVW method is likely to provide the most reliable causal estimates. When exploring the association between MMP-12 levels and VTE, the MR-Egger method (p= 0.087) and the weighted mode method (p= 0.006) appeared to be somewhat inconsistent with the main findings. Although the p-values did not reach statistical significance, the different MR methods (IVW, MR-Egger, and weighted mode) demonstrated directionally consistent results, leading us to consider our results robust.

An advantage of this study is that it employed the MR method to investigate the relationship between MMP levels and VTE, effectively reducing the influence of confounding factors and avoiding erroneous causal associations. The GWAS data for MMPs and VTE were obtained from a large cohort. Furthermore, sensitivity analyses showed no significant horizontal pleiotropy or heterogeneity in our study, and the Steiger directionality test did not indicate any significant reverse causal relationships.

However, our study also had some limitations. First, although the cohort was considerably large, it is important to note that all patients were of European descent. Therefore, the findings may not be applicable to other populations. Second, we investigated only the causal association between five specific MMPs and VTE. The GWAS data for other MMPs were relatively limited, resulting in an extremely small number of SNPs available for analysis. Third, we could not perform a subgroup analysis because the GWAS data consisted only of summary-level statistics. Fourth, the statistical power for the association between MMP-10 and VTE did not reach the 80% threshold, which could be due to the minimal variance in MMP-10 explained by the selected instrumental variables. Therefore, caution is advised when interpreting the results.

In conclusion, this MR study established a causal relationship between MMP-12 levels and VTE, which could significantly impact the diagnostic and therapeutic approaches for VTE. Further research is required to confirm these findings and investigate the underlying mechanisms.

The genetic variants of the serum MMP levels were obtained from a study conducted by Folkersen et al., and the GWAS data of venous thromboembolism were obtained from the FinnGen research project. We thank the participants for sharing the data.

Data availability

All the datasets used in the present study are publicly available. The data generated or analyzed during this study have been included in this published article.

Supplementary materials

Supplementary materials are available at https://doi.org/10.4178/epih.e2024046.

Supplementary Material 1.

Supplementary Material 2.

Supplementary Material 3.

Supplementary Material 4.

Figure 1. Three core assumptions of the 2-sample Mendelian randomization design in this study. ① The instrumental variable is strongly associated with the serum MMP levels. ② The instrumental variable is independent of confounders. ③ The instrumental variable affects the VTE (including DVT and PE) solely via the serum MMP levels. MMP, matrix metalloproteinase; VTE, venous thromboembolism; DVT, deep vein thrombosis; PE, pulmonary embolism.

Figure 2. The causal association between MMP and VTE (including DVT and PE) using the inverse-variance weighted Mendelian randomization method. A p-value <0.0033 was considered statistically significant. A p-value ranging from 0.0033 to 0.0500 was regarded as suggestive evidence. OR, odds ratio; CI, confidence interval; MMP, matrix metalloproteinase; VTE, venous thromboembolism; DVT, deep vein thrombosis; PE, pulmonary embolism.

Figure 3. Trends in the causal associations between (A) the MMP-1 level and PE, (B) the MMP-3 level and PE, (C) the MMP-3 level and DVT, (D) the MMP-7 level and PE, (E) the MMP-10 level and VTE, (F) the MMP-12 level and VTE, and (G) the MMP-12 level and PE. MMP, matrix metalloproteinase; VTE, venous thromboembolism; DVT, deep vein thrombosis; PE, pulmonary embolism; MR, Mendelian randomization.

Table 1. Heterogeneity and pleiotropy tests of the significance of causal effects of MMPs on VTE

Exposure	Outcome	Pleiotropy	Heterogeneity	
Intercept	SE	p-value	Q	p-value	
MMP1	VTE	-0.005	0.006	0.448	52.521	0.059	
MMP1	DVT	0.007	0.009	0.469	54.215	0.053	
MMP1	PE	0.004	0.009	0.658	52.579	0.072	
MMP3	VTE	0.007	0.005	0.148	61.105	0.208	
MMP3	DVT	0.001	0.007	0.841	62.543	0.199	
MMP3	PE	-0.002	0.006	0.760	56.594	0.378	
MMP7	VTE	-0.001	0.007	0.854	21.751	0.194	
MMP7	DVT	0.000	0.009	0.988	11.071	0.853	
MMP7	PE	-0.009	0.010	0.367	20.029	0.219	
MMP10	VTE	0.003	0.007	0.682	38.413	0.072	
MMP10	DVT	0.003	0.009	0.780	36.935	0.120	
MMP10	PE	-0.003	0.010	0.741	42.412	0.030	
MMP12	VTE	0.000	0.004	0.965	62.097	0.159	
MMP12	DVT	-0.001	0.006	0.826	40.464	0.877	
MMP12	PE	0.003	0.007	0.722	82.454	0.005	
MMP, matrix metalloproteinase; VTE, venous thromboembolism; DVT, deep vein thrombosis; PE, pulmonary embolism; SE, standard error.

Conflict of interest

The authors have no conflicts of interest to declare for this study.

Funding

None.

Author contributions

Conceptualization: Han D, Zheng L. Data curation: Han D, Yu F. Formal analysis: Han D, Yu F. Funding acquisition: None. Methodology: Han D. Project administration: Han D, Yu F. Visualization: Han D, Yu F. Writing – original draft: Han D, Yu F. Writing – review & editing: Zheng L.
==== Refs
References

1 Khan F Tritschler T Kahn SR Rodger MA Venous thromboembolism Lancet 2021 398 64 77 10.1016/S0140-6736(20)32658-1 33984268
2 Lutsey PL Zakai NA Epidemiology and prevention of venous thromboembolism Nat Rev Cardiol 2023 20 248 262 10.1038/s41569-022-00787-6 36258120
3 Duffett L Deep venous thrombosis Ann Intern Med 2022 175 ITC129 ITC144 10.7326/AITC202209200 36095313
4 Guntupalli SR Spinosa D Wethington S Eskander R Khorana AA Prevention of venous thromboembolism in patients with cancer BMJ 2023 381 e072715 10.1136/bmj-2022-072715 37263632
5 de Almeida LG Thode H Eslambolchi Y Chopra S Young D Gill S Matrix metalloproteinases: from molecular mechanisms to physiology, pathophysiology, and pharmacology Pharmacol Rev 2022 74 712 768 10.1124/pharmrev.121.000349 35738680
6 Mahalanobish S Saha S Dutta S Sil PC Matrix metalloproteinase: an upcoming therapeutic approach for idiopathic pulmonary fibrosis Pharmacol Res 2020 152 104591 10.1016/j.phrs.2019.104591 31837390
7 Li K Tay FR Yiu CK The past, present and future perspectives of matrix metalloproteinase inhibitors Pharmacol Ther 2020 207 107465 10.1016/j.pharmthera.2019.107465 31863819
8 Chen AY Adamek RN Dick BL Credille CV Morrison CN Cohen SM Targeting metalloenzymes for therapeutic intervention Chem Rev 2019 119 1323 1455 10.1021/acs.chemrev.8b00201 30192523
9 Bräuninger H Krüger S Bacmeister L Nyström A Eyerich K Westermann D Matrix metalloproteinases in coronary artery disease and myocardial infarction Basic Res Cardiol 2023 118 18 10.1007/s00395-023-00987-2 37160529
10 Grillet B Pereira RV Van Damme J Abu El-Asrar A Proost P Opdenakker G Matrix metalloproteinases in arthritis: towards precision medicine Nat Rev Rheumatol 2023 19 363 377 10.1038/s41584-023-00966-w 37161083
11 Piperigkou Z Karamanos NK Estrogen receptor-mediated targeting of the extracellular matrix network in cancer Semin Cancer Biol 2020 62 116 124 10.1016/j.semcancer.2019.07.006 31310807
12 Li W Zhang H Ren A Fan W Qin Q Zhao L Systemic lupus erythematosus is associated with lower risk of hepatitis B virus infection: a multivariable Mendelian randomization study in East Asian population J Med Virol 2023 95 e29226 10.1002/jmv.29226 37997467
13 Emdin CA Khera AV Kathiresan S Mendelian randomization JAMA 2017 318 1925 1926 10.1001/jama.2017.17219 29164242
14 Davies NM Holmes MV Davey Smith G Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians BMJ 2018 362 k601 10.1136/bmj.k601 30002074
15 Lawlor DA Commentary: two-sample Mendelian randomization: opportunities and challenges Int J Epidemiol 2016 45 908 915 10.1093/ije/dyw127 27427429
16 Folkersen L Gustafsson S Wang Q Hansen DH Hedman ÅK Schork A Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals Nat Metab 2020 2 1135 1148 10.1038/s42255-020-00287-2 33067605
17 Tan JS Liu NN Guo TT Hu S Hua L Genetically predicted obesity and risk of deep vein thrombosis Thromb Res 2021 207 16 24 10.1016/j.thromres.2021.08.026 34507265
18 Verbanck M Chen CY Neale B Do R Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases Nat Genet 2018 50 693 698 10.1038/s41588-018-0099-7 29686387
19 Bowden J Spiller W Del Greco M F Sheehan N Thompson J Minelli C Improving the visualization, interpretation and analysis of two-sample summary data Mendelian randomization via the Radial plot and Radial regression Int J Epidemiol 2018 47 1264 1278 10.1093/ije/dyy101 29961852
20 Palmer TM Lawlor DA Harbord RM Sheehan NA Tobias JH Timpson NJ Using multiple genetic variants as instrumental variables for modifiable risk factors Stat Methods Med Res 2012 21 223 242 10.1177/0962280210394459 21216802
21 Chen H Chen S Ye H Guo X Protective effects of circulating TIMP3 on coronary artery disease and myocardial infarction: a Mendelian randomization study J Cardiovasc Dev Dis 2022 9 277 10.3390/jcdd9080277 36005441
22 Huedo-Medina TB Sánchez-Meca J Marín-Martínez F Botella J Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods 2006 11 193 206 10.1037/1082-989X.11.2.193 16784338
23 Bowden J Davey Smith G Burgess S Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression Int J Epidemiol 2015 44 512 525 10.1093/ije/dyv080 26050253
24 Tao T Tang A Lv L Yuan J Wu L Zhao L Investigating the causal relationship and potential shared diagnostic genes between primary biliary cholangitis and systemic lupus erythematosus using bidirectional Mendelian randomization and transcriptomic analyses Front Immunol 2024 15 1270401 10.3389/fimmu.2024.1270401 38464525
25 Liang X Fan Y Bidirectional two-sample Mendelian randomization analysis reveals a causal effect of interleukin-18 levels on postherpetic neuralgia risk Front Immunol 2023 14 1183378 10.3389/fimmu.2023.1183378 37304287
26 Zhao Z Cao Q Zhu M Wang C Lu X Causal relationships between serum matrix metalloproteinases and estrogen receptornegative breast cancer: a bidirectional Mendelian randomization study Sci Rep 2023 13 7849 10.1038/s41598-023-34200-0 37188722
27 Lee KJ Kim H Lee SJ Duperron MG Debette S Bae HJ Causal effect of the 25-hydroxyvitamin D concentration on cerebral small vessel disease: a Mendelian randomization study Stroke 2023 54 2338 2346 10.1161/STROKEAHA.123.042980 37465996
28 Dale CE Fatemifar G Palmer TM White J Prieto-Merino D Zabaneh D Causal associations of adiposity and body fat distribution with coronary heart disease, stroke subtypes, and type 2 diabetes mellitus: a Mendelian randomization analysis Circulation 2017 135 2373 2388 10.1161/CIRCULATIONAHA.116.026560 28500271
29 van Es N Takada T Kraaijpoel N Klok FA Stals MA Büller HR Diagnostic management of acute pulmonary embolism: a prediction model based on a patient data meta-analysis Eur Heart J 2023 44 3073 3081 10.1093/eurheartj/ehad417 37452732
30 Tan R Yuan M Wang L Liu J Jiang G Liao J The pathogenesis of aging-induced left atrial appendage thrombus formation and cardioembolic stroke in mice is influenced by inflammation-derived matrix metalloproteinases Thromb Res 2023 226 69 81 10.1016/j.thromres.2023.04.020 37121014
31 Yu G Li K Xu Y Chu H Zhan H Zhong Y The expression of matrix metalloproteinases and their tissue inhibitors in the vein wall following superficial venous thrombosis Phlebology 2022 37 63 71 10.1177/02683555211043332 34494484
32 Kaireviciute D Blann AD Balakrishnan B Lane DA Patel JV Uzdavinys G Characterisation and validity of inflammatory biomarkers in the prediction of post-operative atrial fibrillation in coronary artery disease patients Thromb Haemost 2010 104 122 127 10.1160/TH09-12-0837 20458440
33 Cárcel-Márquez J Cullell N Muiño E Gallego-Fabrega C Lledós M Ibañez L Causal effect of MMP-1 (matrix metalloproteinase-1), MMP-8, and MMP-12 levels on ischemic stroke: a Mendelian randomization study Stroke 2021 52 e316 e320 10.1161/STROKEAHA.120.033041 33902302
34 Jia Y Guo D Zhang K Yang P Zang Y Sun L Causal associations of serum matrix metalloproteinase-8 level with ischaemic stroke and ischaemic stroke subtypes: a Mendelian randomization study Eur J Neurol 2021 28 2543 2551 10.1111/ene.14878 33894037
35 Zou X Wang L Wang S Zhang Y Ma J Chen L Promising therapeutic targets for ischemic stroke identified from plasma and cerebrospinal fluid proteomes: a multicenter Mendelian randomization study Int J Surg 2024 110 766 776 10.1097/JS9.0000000000000922 38016292
36 Palm F Lahdentausta L Sorsa T Tervahartiala T Gokel P Buggle F Biomarkers of periodontitis and inflammation in ischemic stroke: a case-control study Innate Immun 2014 20 511 518 10.1177/1753425913501214 24045341
37 Hsieh FI Chiou HY Hu CJ Jeng JS Lin HJ Lee JT Combined effects of MMP-7, MMP-8 and MMP-26 on the risk of ischemic stroke J Clin Med 2019 8 2011 10.3390/jcm8112011 31752174
38 Peeters W Moll FL Vink A van der Spek PJ de Kleijn DP de Vries JP Collagenase matrix metalloproteinase-8 expressed in atherosclerotic carotid plaques is associated with systemic cardiovascular outcome Eur Heart J 2011 32 2314 2325 10.1093/eurheartj/ehq517 21289041
39 Kormi I Nieminen MT Havulinna AS Zeller T Blankenberg S Tervahartiala T Matrix metalloproteinase-8 and tissue inhibitor of matrix metalloproteinase-1 predict incident cardiovascular disease events and all-cause mortality in a population-based cohort Eur J Prev Cardiol 2017 24 1136 1144 10.1177/2047487317706585 28429955
40 Tuomainen AM Nyyssönen K Laukkanen JA Tervahartiala T Tuomainen TP Salonen JT Serum matrix metalloproteinase-8 concentrations are associated with cardiovascular outcome in men Arterioscler Thromb Vasc Biol 2007 27 2722 2728 10.1161/ATVBAHA.107.154831 17932311
41 Kennedy R Schneier A Javed M Truong H Recurrent upper extremity arterial thrombosis preceding a diagnosis of COVID-19 Ann Vasc Surg Brief Rep Innov 2023 3 100148 10.1016/j.avsurg.2022.100148 36447618
42 Kerzeli IK Kostakis A Türker P Malmström PU Hemdan T Mezheyeuski A Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer BMC Cancer 2023 23 605 10.1186/s12885-023-11100-0 37391708
43 Zhou X Zhang C Yang S Yang L Luo W Zhang W Macrophage-derived MMP12 promotes fibrosis through sustained damage to endothelial cells J Hazard Mater 2024 461 132733 10.1016/j.jhazmat.2023.132733 37816293
44 Stawski L Haines P Fine A Rudnicka L Trojanowska M MMP12 deficiency attenuates angiotensin II-induced vascular injury, M2 macrophage accumulation, and skin and heart fibrosis PLoS One 2014 9 e109763 10.1371/journal.pone.0109763 25302498
45 Aristorena M Gallardo-Vara E Vicen M de Las Casas-Engel M Ojeda-Fernandez L Nieto C MMP-12, secreted by pro-inflammatory macrophages, targets endoglin in human macrophages and endothelial cells Int J Mol Sci 2019 20 3107 10.3390/ijms20123107 31242676
46 Amor M Bianco V Buerger M Lechleitner M Vujić N Dobrijević A Genetic deletion of MMP12 ameliorates cardiometabolic disease by improving insulin sensitivity, systemic inflammation, and atherosclerotic features in mice Cardiovasc Diabetol 2023 22 327 10.1186/s12933-023-02064-3 38017481
47 Belaaouaj AA Li A Wun TC Welgus HG Shapiro SD Matrix metalloproteinases cleave tissue factor pathway inhibitor. Effects on coagulation J Biol Chem 2000 275 27123 27128 10.1016/S0021-9258(19)61488-2 10859319
48 Challa SR Nalamolu KR Fornal CA Mohandass A Mussman JP Schaibley C The interplay between MMP-12 and t-PA in the brain after ischemic stroke Neurochem Int 2022 161 105436 10.1016/j.neuint.2022.105436 36283468
49 Koolwijk P Sidenius N Peters E Sier CF Hanemaaijer R Blasi F Proteolysis of the urokinase-type plasminogen activator receptor by metalloproteinase-12: implication for angiogenesis in fibrin matrices Blood 2001 97 3123 3131 10.1182/blood.V97.10.3123 11342439
